Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BeOne Medicines AG (NASDAQ:ONC) is one of the most promising stocks on our list.

TheFly reported on June 2 that RBC Capital analyst Leonid Timashev increased the firm’s price target on ONC to $436 from $425 while maintaining an Outperform rating on the shares. The update followed the company’s ASCO presentations featuring three oncology programs, including a CDK4 inhibitor for breast cancer, a GPC3-41BB bispecific candidate for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer. RBC Capital noted that these assets demonstrated encouraging potential, with differentiated safety or efficacy profiles that could position them as leading therapies or strong competitors in their respective markets over time.

Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?

More recently, on June 11, BeOne Medicines AG (NASDAQ:ONC) presented Phase 3 data from the SEQUOIA trial in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The analysis, including nearly 6.5 years of follow-up, showed sustained clinical benefits with Brukinsa, highlighting its continued role as a leading BTK inhibitor option. Data from older patients aged 80 and above demonstrated that advanced age did not reduce treatment benefits. The findings further supported Brukinsa’s strong efficacy and safety profile, reinforcing its potential position as a foundational therapy in CLL. The dataset will be presented at the 2026 European Hematology Association Congress.

BeOne Medicines AG (NASDAQ:ONC) is a global oncology company developing and commercializing innovative targeted therapies and immuno-oncology treatments to improve access to cancer care worldwide.

While we acknowledge the risk and potential of ONC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ONC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1